Kidney Tumor Program

Meet the Team

The Kidney Tumor Program, part of the Cancer and Blood Diseases Institute, is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs.

Show All

Medical Director

Hide

James I. Geller, MD Medical Director, Kidney and Liver Tumors Program 513-636-4266 james.geller@cchmc.org

High Res

James I. Geller, MD

Medical Director, Kidney and Liver Tumors Program

Co-Medical Director, Retinoblastoma Program

Associate Director, Global Cancer Programs

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-4266

Fax 513-636-3549

Email james.geller@cchmc.org

Show All

Clinical & Research Interests

Show

Clinical

Developmental therapeutics; renal / liver / retinoblastoma / neuro-oncology

Research

Elucidating ways to translate the use of biological response modifiers in combination with conventional chemotherapeutics

Biography

Show

James I. Geller, MD, completed his undergraduate training at Dartmouth College, graduate medical training at the Sackler School of Medicine, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children's Research Hospital. His current appointment is with Cincinnati Children's Hospital Medical Center within the University of Cincinnati in the capacity of professor of pediatrics.

Dr. Geller's clinical and academic interests pertain to children and families affected by solid tumors, including brain tumors. Dr. Geller's expertise is recognized both nationally and internationally in the fields of retinoblastoma, renal tumors, liver tumors and brain tumors, as witnessed by his appointments to the Children's Oncology Group (COG) Rare / Retinoblastoma Committee as both a steering/voting member and as liaison to the COG Young Investigator Committee; the COG Renal Tumor Committee (RTC) as steering/voting member, RTC Sub-Committee chair of developmental therapeutics, and RTC liaison to both the COG Developmental Therapeutics Committee and the Pediatric Preclinical Testing Program Guidance Committee; and to the Central Nervous System (Brain Tumor) Committee as a voting member. Dr. Geller has been an invited speaker at numerous national and international meetings and symposia and spearheads both local and national clinical research initiatives in these areas, with an emphasis on finding new treatment options.

Education and Training

Show

MD: Sackler School of Medicine, 1997.

Residency: New York Medical College, 2000.

Fellowship: St Jude Children's Research Hospital, 2004.

Certification: Pediatrics, 2000, 2007; Pediatric Hematology / Oncology, 2005.

Publications

Show

View PubMed Publications

Geller JI, Meyers AB, Towbin AJ, Serai S, Geller JI, Podberesky DJ. Characterization of pediatric liver lesions with gadoxetate disodium. Pediatr Radiol. 2011 Sep;41(9):1183-97.

Pressey JG, Wright JM, Geller JI, Joseph DB, Pressey CS, Kelly DR. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer. 2010 Jul 1;54(7):1035-7.

Cripe TP. Adenovirus gene therapy for pediatric cancers: shall we gather at the liver? Pediatr Blood Cancer. 2009 Aug;53(2):133-5.

Geller JI, Dome JS. Retroperitoneal lymph node dissection for pediatric renal cell carcinoma. Pediatr Blood Cancer. 2009 Mar;52(3):430.

Geller JI, Leslie ND, Yin H. Malignant Rhabdoid Tumor. eMedicine from WebMD. 2009 Dec. Available online.

Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.

Geller JI. Genetic stratification of Wilms tumor: is WT1 gene analysis ready for prime time? Cancer. 2008 Sep 1;113(5):893-6.

Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins MH. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008 Apr 1;112(7):1607-16.

Geller JI, Dome JS. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Pediatr Blood Cancer. 2006 Apr;46(4):527.

Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004 Oct 1;101(7):1575-83.

Oncologists

Show

Rajaram Nagarajan, MD, MS Clinical Director, Division of Oncology 513-636-0670 rajaram.nagarajan@cchmc.org

High Res

Rajaram Nagarajan, MD, MS

Clinical Director, Division of Oncology

Director, Cancer Control and Outcomes Research, Cancer Survivor Center

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-0670

Fax 513-636-3549

Email rajaram.nagarajan@cchmc.org

Show All

Clinical & Research Interests

Show

Clinical

Bone tumors; late effects of pediatric cancer therapy

Research

Outcomes following cancer therapy and bone sarcomas

Education and Training

Show

BA: Pre-Medical Sciences, Lehigh University, Bethlehem, PA, 1991.

MD: Medical College of Pennsylvania, Philadelphia, PA, 1995.

Internship and Residency: Pediatrics, Medical College of Virginia, Richmond, VA, 1998.

Fellowship Training: Hematology / Oncology / BMT, University of Minnesota, Minneapolis, MN, 2002.

MS: Clinical Research, University of Minnesota, Minneapolis, MN, 2002.

Certifications: Pediatrics, Pediatric Hematology / Oncology.

Publications

Show

View PubMed Publications

Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, Yasui Y, Robison LL, Marina N. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the childhood cancer survivor study. Cancer. 2011 Feb 1;117(3):625-34.

Rayburg M, Towbin A, Yin H, Maugans T, Maurer B, Nagarajan R, Weiss B. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. Pediatr Blood Cancer. 2009 Dec;53(6):1111-3.

Nagarajan R. Quality of life (QOL) in patients with osteosarcoma. Recent Results Cancer Res. 2009;179:339-44.

Nagarajan R, Mogil R, Neglia JP, Robison LL, Ness KK. Self-reported global function among adult survivors of childhood lower-extremity bone tumors: a report from the Childhood Cancer Survivor Study (CCSS). J Cancer Surviv. 2009 Mar;3(1):59-65.

Zebrack BJ, Zevon MA, Turk N, Nagarajan R, Whitton J, Robison LL, Zeltzer LK. Psychological distress in long-term survivors of solid tumors diagnosed in childhood: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2007 Jul;49(1):47-51.

Khan K, Schwarzenberg SJ, Sharp H, Jessurun J, Gulbahce HE, Defor T, Nagarajan R. Diagnostic endoscopy in children after hematopoietic stem cell transplantation. Gastrointest Endosc. Sep 2006;64(3):379-85.

Schultz KA, Ness KK, Nagarajan R, Steiner ME. Adnexal masses in infancy and childhood. Clinical Obstetrics and Gynecology. Sep 2006; 49(3):464-79.

Nagarajan R, Clohisy D, Weigel B. New paradigms for therapy for osteosarcoma. Curr Oncol Rep. 2005 Nov;7(6):410-4.

Nagarajan R, Robison LL. Pregnancy outcomes in survivors of childhood cancer. J Natl Cancer Inst Monogr. 2005;(34):72-6.

Book Chapters

Spector LG, Ross JA, Nagarajan R. Epidemiology of bone and soft tissue sarcomas. In Pappo A (Ed.) Pediatric Bone and Soft Tissue Tumors. 1st ed. Berlin: Springer-Verlag, 2006.

Brian D. Weiss, MD Medical Director, Neuroblastoma Program 513-636-9863 brian.weiss@cchmc.org

High Res

Brian D. Weiss, MD

Medical Director, Neuroblastoma Program

Associate Director of Clinical Research for Oncology

Associate Director for Safety and Compliance

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-9863

Fax 513-636-3549

Email brian.weiss@cchmc.org

Show All

Clinical Interests

Show

Targeted agents for neurofibromatosis type 1-related plexiform neurofibromas and other solid tumors; new therapies for high-risk neuroblastoma, including 131I-MIBG treatment and other new approaches to targeting and killing neuroblastoma cells.

Biography

Show

Brian Weiss is a professor of Clinical Pediatrics in the Cancer and Blood Diseases Institute at Cincinnati Children’s Hospital Medical Center. There, he specializes in benign tumors in patients with Neurofibromatosis Type 1 (NF1), and directs the Neuroblastoma Program, in addition to serving as associate director of clinical research for Oncology, and associate director for Safety and Compliance. Dr. Weiss has spearheaded efforts to reduce chemotherapy errors and leads national trials in high risk neuroblastoma, targeted radiotherapy, and targeted drugs for NF1 associated plexiform neurofibromas.

Education and Training

Show

MD: Northwestern University Medical School, Chicago, IL, 1993.

Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997.

Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000.

Certification: National Medical Board; Pediatrics;1996, 2002; Pediatric Hematology-Oncology, 2000, 2007.

Publications

Show

View PubMed Publications

Sharp SE, Trout AT, Weiss B, Gelfand M. MIBG in Neuroblastoma Diagnostic Imaging and Therapy. Radiographics. 2016 Jan-Feb;36(1):258-78.

Adams DM, Trenor CC 3rd, Hammill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C, Gupta A, Chute C, Eile J, McKenna J, Merrow AC, Fei L, Hornung L, Seid M, Dasgupta AR, Dickie BH, Elluru RG, Lucky AW, Weiss B, Azizkhan RG. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics. 2016 Feb;137(2):1-10.

Dandoy CE, Hariharan S, Weiss B, Demmel K, Timm N, Chiarenzelli J, Dewald MK, Kennebeck S, Langworthy S, Pomales J, Rineair S, Sandfoss E, Volz-Noe P, Nagarajan R, Alessandrini E. Sustained reductions in time to antibiotic delivery in febrile immunocompromised children: results of a quality improvement collaborative. BMJ Qual Saf. 2016 Feb;25(2):100-9.

DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen EC, Giacomini KM, Weiss B, Cohn SL, Granger M, Yanik GA, Hawkins R, Courtier J, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei DD, Villablanca JG, Marachelian A, Matthay KK. Phase 1 Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15;21(12):2715-21.

Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. Biol Blood Marrow Transplant. 2015 Apr;21(4):673-81.

Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, Perentesis J, Schorry E, Ullrich N, Gutmann DH, Tonsgard J, Viskochil D, Korf B, Packer RJ, Fisher MJ. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015 Apr;17(4):596-603.

Salloum R, Garrison A, von Allmen D, Sheridan R, Towbin AJ, Adams D, Weiss B. Relapsed perinatal neuroblastoma after expectant observation. Pediatr Blood Cancer. 2015 Jan;62(1):160-2.

Emoto C, Fukuda T, Mizuno T, Cox S, Schniedewind B, Christians U, Widemann BC, Fisher MJ, Weiss B, Perentesis J, Vinks AA. Age dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. Ther Drug Monit. 2015 Jun;37(3):395-9.

Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, Parkinson DB, Stemmer-Rachamimov AO, Van Raamsdonk CD, Riccardi VM, Rosser T, Schindeler A, Smith MJ, Stevenson DA, Ullrich NJ, van der Vaart T, Weiss B, Widemann BC, Zhu Y, Bakker AC, Lloyd AC. Update from the 2013 international neurofibromatosis conference. Am J Med Genet A. 2014 Dec;164A(12):2969-78.

Dandoy C, Davies S, Flesch L, Hayward M, Koons C, Coleman K, Jacobs J, McKenna L, Olomajeye A, Olson C, Powers J, Shoemaker K, Jodele S, Alessandrini E, Weiss B. A Team-Based Approach to Reducing Cardiac Monitor Alarms. Pediatrics. 2014 Dec;134(6)e1686-94.

Kidney Tumor Program